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Dear Editor 
The lattice corneal dystrophies (LCD) are characterized by 
an accumulation of amyloid within the cornea. There are 
several types of LCD, and in the LCD2 type the corneal 
features are subtly unique. The lattice lines are finely 
arranged and tend to be denser in the periphery (1,2). 
Corneal erosions occur less frequently, and visual acuity 
is preserved until the sixth decade (2). Lattice corneal 
dystrophie 2 is associated with systemic amyloidosis type 
V (Meretoja syndrome/Finnish type) (1-4). This is a 
systemic autosomal dominant disease that arises in early 
adulthood and predominantly affects the cornea, skin, 
and cranial nerves (2,3). Amyloid deposition corresponds 
to a degradation product of gelsolin. Amyloidosis type V 
was first described in Finland (3) where it occurs with 
high frequency (1). New cases have been reported in 
several other countries (5). Regular biomicroscopic 
examination and intraocular pressure measurements are 
recommended since the disease is incurable and amyloid 
deposition will continue. When significant central corneal 
haze is present, only keratoplasty can clarify the cornea 
and restore vision. However, the graft could accumulates 
new amyloid. Slight-documentation of these grafts has 
been reported to survive. We recently reoperated on a 
Spanish patient with Meretoja syndrome (5). The patient 
suffered a graft rejection two years after a corneal 
transplant in the left eye. Months later a neurotrophic 
central defect was present in the cornea with progressive 
accumulation of a white substance suspected to be 
amyloid material (Fig. 1). 
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Figure 1. White deposits in the corneal button 8 years after 
keratoplasty in LCD2. 
 
Figure 2. Congo red shows deposition of material under Bowman´s 
layer in LCD2 (A). 
 
Recurrent amyloid in the corneal button in the same pattern as 
previously (B). 
 
Biomicroscopical examination showed a white area 
surrounding the corneal vessels similar in appearance to 
the lipid leakage from corneal stromal vessels (Fig.1). 
Vascular leakage could have led to amyloid deposition, 
rather than real dystrophy recurrence.  
Given the total failure of the graft, a new penetrating 
keratoplasty was decided. The procedure was performed 
without complications in March 2014, 8 years after the 
first keratoplasty.  
Histology of the corneal button showed fibrosis and 
changes secondary to the previous surgical procedure. 
Subepithelial deposits of amyloid were seen with a 
pattern identical to that of the first surgical specimen 
(Fig. 2). In LCD2, the amyloid marker Congo red will show 
deposition of material under Bowman’s layer and in 
some cases at the level of the epithelial basal membrane. 
The disease is under-reported. Originally, the material 
was believed to arise from degenerated nerves but now 
it is believed to be locally produced amyloid (6). Some 
authors feel that the disease may recur in the graft (1). 
According to our observations, the amyloid tends to 
recur in the grafted button with a similar distribution. 
Despite graft rejection, progressive amyloid 
accumulation under Bowman’s membrane may 
contribute to graft failure. Our findings suggest that in 
LCD2, keratoplasty is not recommended until vision is 
indigent because the disease may recur after a short time 
and graft survival will be limited to a few years. 
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